Board brings deep expertise in pain medicine, regulatory strategy, biologics manufacturing, and blood-derived therapeutics to guide the company’s first-in-class program

BURLINGTON, MA — February 13, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101 into clinical development for chronic lumbosacral radiculopathy (LSR), or chronic sciatica.

Consano’s Scientific Advisory Board is composed of recognized leaders in regulatory affairs, pain medicine, transfusion science, and biologics development. The SAB provides strategic guidance across clinical trial design, translational science, manufacturing, and regulatory pathways, helping ensure that Consano’s approach is grounded in rigorous science and aligned with the highest standards of pharmaceutical development.

“Chronic sciatica represents one of the largest unmet needs in pain medicine, and it demands both scientific innovation and disciplined execution,” said Andrew Hall, Chief Executive Officer of Consano Bio. “We are fortunate to work with a Scientific Advisory Board that brings deep expertise across clinical care, regulatory strategy, and biologics development. Their insight is invaluable as we advance C-1101 into the clinic and pursue our goal of developing a disease-modifying, non-opioid therapy for patients who currently have few effective options.”

Members of Consano Bio’s Scientific Advisory Board include:

• Susan Stewart, JD, LL.M, RAC, FRAPS, a regulatory affairs and quality assurance leader with more than 35 years of experience guiding global regulatory strategies for drugs and biologics at companies including Genzyme, Frequency Therapeutics, Kaleido Biosciences, and Tokai Pharmaceuticals.
• Mihir Kamdar, MD, a Pain Medicine and Palliative Care physician at Massachusetts General Hospital and faculty member at Harvard Medical School, with extensive clinical and research experience focused on refractory pain and innovative treatment models for symptom management.
• Ralph Vassallo, MD, Executive Vice President and Chief Scientific and Medical Officer at Vitalant, with decades of leadership in transfusion medicine, donor health, and blood-based therapeutic science, and more than 100 peer-reviewed publications.
• Li Malmberg, PhD, a veteran CMC executive with nearly 30 years of experience in biologics development and manufacturing, including senior leadership roles at Celgene, AbbVie, Magenta Therapeutics, and Xilio Therapeutics, where she guided multiple programs from clinical development through regulatory approval.

“I am thrilled to join Consano Bio’s Scientific Advisory Board at such a pivotal phase in the company’s growth,” stated Mihir Kamdar, MD. “There is a profound need for better treatments in the field of lumbosacral radiculopathy. Along with my fellow board members, I look forward to contributing our collective clinical and scientific expertise to help lead this innovation. Consano’s approach is truly transformative, and we are committed to delivering a meaningful, disease-modifying solution to the millions of patients sidelined by chronic pain.”

Together, the Scientific Advisory Board supports Consano Bio’s mission to to transform the treatment of painful and debilitating orthopedic conditions through a new class of multi-protein therapeutics.

About Consano Bio
Consano Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of painful and debilitating orthopedic conditions through a new class of multi-protein therapeutics. Founded in 2023 and headquartered in the Greater Boston area, the company is developing C-1101, a potential first-in-class pharmaceutical therapy for chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The therapy is designed to deliver a high concentration of these proteins from human platelets directly to the site of injury to modulate inflammation and promote localized tissue repair. For more information, visit www.consanobio.com.

Contacts 

Investor Relations
Tiberend Strategic Advisors, Inc. 
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Eric Reiss
ereiss@tiberend.com